Log in


  • Home
  • ODS MONTHLY MEETING


Copyright © Oregon Dermatology Society

ODS MONTHLY MEETING

  • 11/09/2022
  • 12:00 PM - 6:00 PM
  • OHSU Rood Family Pavilion Conference Room - 3410 SW Bond Ave, Portland

Registration

  • ODS Members

Registration is closed

Featuring Avrom Caplan, MD from New York University


 12:00-1:00 Lunch Lecture - Management Strategies in Medical Dermatology: Challenging Cases and Getting Started Avrom Caplan, MD
 1:00-1:30

Informational Talk Sponsored by Regeneron - Multidisciplinary Management of Advanced CSCC and Locally Advanced BCC


Nathalie Zeitouni, MD CM, FRCPC
 1:30-3:00 Patient Viewing & Case Discussion - Submit a Case Online Tracy Funk, MD (moderator)
 3:00-3:15 Networking Break  
 3:15-3:30 Resident Lecture 1 Gregory Phillips, MD
 3:30-3:45 Resident Lecture 2  Erin Grinich, MD
 3:45-4:00 OHSU/ODS Updates Tracy Funk, MD; Sancy Leachman, MD, PhD
 4:00-5:00 Keynote Lecture - Non-Infectious Granulomas of the Skin: Presentation, Implications Management, Advances  Avrom Caplan, MD
 5:00-6:00 Reception  


Learning Objectives:

1) List helpful resources you can use when graduating from residency to being an attending in medical dermatology clinics

2) Outline and implement treatment strategies in medical dermatology using a case-based approach

3) Assess, troubleshoot, and implement changes in management for "refractory" cutaneous disease

Sarcoidosis: the dermatologist role and advances in management

1) Describe patients at risk for severe sarcoidosis of the skin

2) Determine implications of specific lesions of sarcoidosis 

3) Summarize workup for sarcoidosis patients presenting to dermatology

4) Choose treatment based on a therapeutic stepladder for skin disease

Granuloma annulare: epidemiology, associated conditions, therapeutics

1) Define the incidence and prevalence of GA

2) Recognize associations with systemic conditions and evaluate patients

3) Describe updates in GA pathogenesis

4) Assess recent updates in GA treatment

Reactive granulomatous dermatitis: IGD/PNGD under a unified umbrella

1) Outline the clinicopathologic features of IGD and PNGD

2) List common drug culprits of drug induced forms of IGD

3) Describe systemic conditions associated with RGD

4) Recognize that IGD/PNGD overlap, and utilize the term RGD

Exhibitors: To join our mailing list for future exhibit opportunities, please send an email to: exhibitors+subscribe@oregondermatology.org

Powered by Wild Apricot Membership Software